Please Wait.....
Report
South America Insulin Market Forecast to 2028 - COVID-19 Impact and Regional Analysis - by Type (Long Acting Insulin, Rapid Acting Insulins, Short acting Insulins and Traditional Human Insulins, Concentrated Insulins and Combination Insulins, Biosimilar Insulins, Glucagon-like peptide-1 (GLP-1), Pens and Needles, and Others)
Market Report I 2022-10-20 I 177 Pages I The Insight Partners
The insulin market in SAM is expected to grow from US$ 4,868.81 million in 2022 to US$ 8,930.46 million by 2028. It is estimated to grow at a CAGR of 10.6% from 2022 to 2028.
Rapid Technological Developments in Insulin Delivery Devices by Major Players
Products with advanced insulin technology with more effective benefits are a major requirement in the treatment of diabetes. There has been a rise in advancements in diabetes treatment over the past few years. As the prevalence of diabetes is increasing across region, the demand for more advanced products is also boosting. The insulin market is expected to grow owing to an increase in the strategic efforts made by the industry players. The market players actively support their public and private research and academic institutes for increasing research activities.
A few of the recent developments related to rapid technological advancement in the insulin market are mentioned below:
- In October 2021, Tonghua Dongbao Pharmaceutical Co., Ltd. received approval from the National Medical Products Administration (NMPA) for the clinical trial of its ultra-rapid-acting insulin lispro injection, BC Lispro. Currently, the drug is under phase III clinical trial initiated in China.
- In May 2021, Bigfoot Biomedical received 510(k) clearance by USFDA for its Bigfoot Unity Diabetes Management System, which features connected smart pen caps that recommend insulin doses for people using multiple daily injections (MDI) therapy.
Thus, rapid technological advancements in insulin delivery devices are boosting the growth of the SAM insulin market.
Market Overview
The SAM insulin market is segmented into Argentina, Brazil, and the Rest of SAM. The market growth is attributed to the increasing occurrence of diabetes (both type I and type II) in the region. Furthermore, regulatory frameworks favoring the operations of insulin manufacturers encourage various multinational companies to establish their production units in SAM countries. According to International Diabetes Federation, 33 million adults (20-79 years) were living with diabetes in SAM in 2021. The figure is estimated to rise to 40 million by 2030 and 49 million by 2045. Per the report, 15.7 million adults are living with diabetes in Brazil, representing 1 in 10 adults. The increasing incidence of diabetes is leading to the degradation of the quality of life of patients. According an article published in the Annals of Global Health, in November 2019, the diabetes epidemic affects most countries across the world and has alarming infection rates in Latin American countries. ~12 million individuals have diabetes in Brazil, with the current prevalence ranging from 6.3% to 13.5%. The rising diabetes prevalence has further translated into a 60% growth in the related risk ratio for cardiovascular diseases associated with diabetes.
Exhibit: SAM Insulin Market Revenue and Forecast to 2028 (US$ Million)
SAM Insulin Market Segmentation
The SAM insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.
Based on long acting insulin, the SAM insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022. Based on short acting insulin and traditional human insulin, the SAM insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.
Based on concentrated insulin and combination insulin, the SAM insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022. Based on biosimilar insulin, the SAM insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022. Based on country, the market is segmented into Brazil, Argentina, and Rest of SAM. Rest of SAM dominated the market share in 2022. Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.
TABLE OF CONTENTS
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Insulin Market - By Type
1.3.2 SAM Insulin Market - By Country
2. SAM Insulin Market - Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Insulin Market - Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.2.1 Expert Opinion
5. SAM Insulin Market- Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market- SAM Analysis
6.1 SAM Insulin Market Revenue Forecast and Analysis
7. SAM Insulin Market Analysis - By Type
7.1 Overview
7.2 SAM Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
8. SAM Insulin Market - Country Analysis
8.1 Overview
8.1.1 SAM Insulin Market Revenue and Forecast to 2028, by Country (%)
8.1.1.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.1.1 Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.1.2 Brazil: Insulin Market, By Type, 2019-2028 (US$ Million)
8.1.1.1.2.1 Brazil: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
8.1.1.1.2.2 Brazil: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
8.1.1.1.2.3 Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
8.1.1.1.2.4 Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
8.1.1.1.2.5 Brazil: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.1.1.2 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.2.1 Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.2.2 Argentina: Insulin Market, By Type, 2019-2028 (US$ Million)
8.1.1.2.2.1 Argentina: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
8.1.1.2.2.2 Argentina: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
8.1.1.2.2.3 Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
8.1.1.2.2.4 Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
8.1.1.2.2.5 Argentina: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
8.1.1.3 Rest of SAM: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.3.1 Rest of SAM: Insulin Market - Revenue and Forecast to 2028 (USD Million)
8.1.1.3.2 Rest of SAM: Insulin Market, By Type, 2019-2028 (US$ Million)
8.1.1.3.2.1 Rest of SAM: Insulin Market, By Long Acting Insulin, 2019-2028 (US$ Million)
8.1.1.3.2.2 Rest of SAM: Insulin Market, By Rapid Acting Insulin, 2019-2028 (US$ Million)
8.1.1.3.2.3 Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019-2028 (US$ Million)
8.1.1.3.2.4 Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019-2028 (US$ Million)
8.1.1.3.2.5 Rest of SAM: Insulin Market, By Biosimilar Insulins, 2019-2028 (US$ Million)
9. SAM Insulin Market-Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 GlaxoSmithKline plc.
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Sanofi
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Pfizer Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Merck & Co., Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms
LIST OF TABLES
Table 1. SAM Insulin Market, Revenue and Forecast, 2019-2028 (US$ Million)
Table 2. Brazil: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 3. Brazil: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 4. Brazil: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 5. Brazil: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 6. Brazil: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. Brazil: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 8. Argentina: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 9. Argentina: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 10. Argentina: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 11. Argentina: Insulin Market, By Short-acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 12. Argentina: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Argentina: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 14. Rest of SAM: Insulin Market, By Type - Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of SAM: Insulin Market, By Long Acting Insulin - Revenue and forecast to 2028 (US$ Million)
Table 16. Rest of SAM: Insulin Market, By Rapid Acting Insulin - Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of SAM: Insulin Market, By Short acting Insulins and Traditional Human Insulins - Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of SAM: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. Rest of SAM: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 20. Organic Developments in the Insulin Market
Table 21. Inorganic Developments in the Insulin Market
Table 22. Glossary of Terms, SAM Insulin Market
LIST OF FIGURES
Figure 1. SAM Insulin Market Segmentation
Figure 2. SAM Insulin Market Segmentation, By Country
Figure 3. SAM Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Rest of SAM Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. South America PEST Analysis
Figure 8. Expert Opinion
Figure 9. SAM Insulin Market Impact Analysis of Drivers and Restraints
Figure 10. SAM Insulin Market- Revenue Forecast and Analysis
Figure 11. SAM Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 12. SAM Long Acting Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 13. SAM Levemir: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 14. SAM Lantus: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 15. SAM Basaglar: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 16. SAM Tresiba: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 17. SAM Rapid Acting Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 18. SAM Novolog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 19. SAM Humalog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 20. SAM Admelog: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 21. SAM Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 22. SAM Short Acting Insulins and Traditional Human Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 23. SAM Novolin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 24. SAM Humulin R: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 25. SAM Insuman: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 26. SAM Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 27. SAM Concentrated Insulins and Combination Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 28. SAM NovoMix: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 29. SAM Ryzodeg: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 30. SAM Xultophy: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 31. SAM Soliqua/Suliqua: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 32. SAM Biosimilar Insulins: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 33. SAM Insulin Glargine: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 34. SAM Human Insulin: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 35. SAM Glucagon-like peptide-1 (GLP-1): Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 36. SAM Pens and Needles: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 37. SAM Others: Insulin Market - Revenue and Forecast to 2028 (US$ Million)
Figure 38. SAM Insulin Market Revenue Overview, By Country (2021) (US$ Mn)
Figure 39. SAM Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 40. Brazil: Insulin Market - Revenue and Forecast to 2028 (USD Million)
Figure 41. Argentina: Insulin Market - Revenue and Forecast to 2028 (USD Million)
Figure 42. Rest of SAM: Insulin Market - Revenue and Forecast to 2028 (USD Million)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security